---
trial_id: 1073
discovery_date: 2022-07-11 14:50:17.098197
date: 2022-07-11 14:50:17.098197
title: "A Phase I&#x2F;Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15&#x2F;sIL-15RÎ±)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma"
summary: |
  
link: 'https://www.novartis.com//clinicaltrials/study/nct04261439'
published_date: NaT
trial_source: Novartis
relevant: 
options:
  unlisted: false
---
